Related Experiment Video
Updated: Nov 30, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Novel approaches to management of hypertension
Agnes Bosch1, Roland E Schmieder
1Department of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.
Insights
New hypertension treatments focus on combination therapy and single-pill combinations for better blood pressure control. Renal denervation is a promising interventional therapy, but patient selection needs refinement.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Hypertension affects 1.4 billion globally, with poor control in most cases.
- Current guidelines emphasize target organ damage and cardiovascular risk assessment.
Purpose of the Study:
- To review novel therapeutic strategies for managing hypertension.
- To highlight recent advancements in antihypertensive treatment approaches.
Main Methods:
- Review of recent clinical studies and updated hypertension guidelines.
- Analysis of data from clinical trials on renal denervation (RDN).
Main Results:
- Shift towards combination therapy and single-pill combinations (SPCs) for improved adherence and blood pressure (BP) control.
- RDN demonstrates consistent and durable BP reductions without significant adverse events.
- Identification of patient subgroups who benefit most from interventional therapies is ongoing.
Conclusions:
- Individualized therapy based on cardiovascular risk is crucial.
- Combination therapy, particularly SPCs, should be the initial treatment approach.
- RDN presents a promising interventional option for select hypertension patients.
Purpose Of Review:
Of the roughly 1.4 billion people with hypertension worldwide, only about one in seven has their blood pressure (BP) successfully treated and adequately controlled. This review will focus on new therapeutic approaches of hypertension.
Recent Findings:
Several recent clinical studies and guidelines have favoured the assessment of target organ damage and cardiovascular risk scores for the diagnosis and treatment approach of hypertension. Paradigm shifts recommended in the guidelines are the initiation of antihypertensive treatment with combination (not mono) therapy and the recommendation of single-pill combinations (SPC), which improve adherence and result in rapid and effective BP control. In clinical trials with optimized design and renal denervation (RDN) technology, the biological proof of concept has been established. Consistent, durable ambulatory and office BP reductions without procedure associated serious adverse events have been documented. The challenges are now to identify patients who respond best to interventional treatment.
Summary:
Major key points in the treatment strategy for hypertension are: individualization of the therapy according to total cardiovascular risk, combination therapy as initial step, recommendation of SPC and RDN as promising interventional therapy.
Related Concept Videos
Hypertension V: Nursing Management
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension and Regulation of Blood Pressure
Hypertension III: Clinical Manifestations and Diagnostic Studies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management

